On April 8, 2021, the clinical trial application of HG381 for injection, developed by HitGen, was approved by National Medical Products Administration (NMPA). HG381 for injection is a new Category I Chemical Drug and is clinically intended to be used for the treatment of advanced tumors. HG381 is new molecular entity developed by HitGen basedRead more